Genprex Toekomstige groei
Future criteriumcontroles 0/6
Genprex's earnings are forecast to decline at 12.2% per annum. EPS is expected to grow by 97.2% per annum.
Belangrijke informatie
-12.2%
Groei van de winst
97.2%
Groei van de winst per aandeel
Biotechs winstgroei | 27.1% |
Inkomstengroei | n/a |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 13 Aug 2024 |
Recente toekomstige groei-updates
Recent updates
Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?
Aug 16Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation
Jan 31Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans
Oct 12Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer
Aug 15We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate
Jun 14Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation
Feb 09Genprex: Limited Clinical Data To Justify Risk
Nov 19We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth
Oct 27Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans
Jun 11Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%
May 05Genprex' stock jumps after corporate update
Feb 01Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials
Jan 13Genprex completes manufacturing scale-up of lung cancer therapy
Dec 22Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2025 | N/A | -29 | N/A | N/A | 1 |
12/31/2024 | N/A | -26 | N/A | N/A | 1 |
6/30/2024 | N/A | -26 | -21 | -21 | N/A |
3/31/2024 | N/A | -28 | -23 | -23 | N/A |
12/31/2023 | N/A | -31 | -25 | -25 | N/A |
9/30/2023 | N/A | -31 | -24 | -24 | N/A |
6/30/2023 | N/A | -30 | -24 | -24 | N/A |
3/31/2023 | N/A | -28 | -21 | -20 | N/A |
12/31/2022 | N/A | -24 | -18 | -18 | N/A |
9/30/2022 | N/A | -24 | -17 | -16 | N/A |
6/30/2022 | N/A | -21 | -14 | -14 | N/A |
3/31/2022 | N/A | -19 | -13 | -13 | N/A |
12/31/2021 | N/A | -21 | -14 | -14 | N/A |
9/30/2021 | N/A | -19 | -17 | -15 | N/A |
6/30/2021 | N/A | -18 | -17 | -14 | N/A |
3/31/2021 | N/A | -19 | -17 | -15 | N/A |
12/31/2020 | N/A | -18 | -16 | -14 | N/A |
9/30/2020 | N/A | -15 | -12 | -12 | N/A |
6/30/2020 | N/A | -15 | -12 | -12 | N/A |
3/31/2020 | N/A | -14 | -11 | -10 | N/A |
12/31/2019 | N/A | -11 | -8 | -7 | N/A |
9/30/2019 | N/A | -12 | -8 | -7 | N/A |
6/30/2019 | N/A | -11 | -8 | -7 | N/A |
3/31/2019 | N/A | -14 | -8 | -8 | N/A |
12/31/2018 | N/A | -12 | -7 | -7 | N/A |
9/30/2018 | N/A | -10 | -5 | -5 | N/A |
6/30/2018 | N/A | -8 | -4 | -4 | N/A |
3/31/2018 | N/A | -3 | N/A | -2 | N/A |
12/31/2017 | N/A | -3 | N/A | -2 | N/A |
9/30/2017 | N/A | -4 | N/A | -3 | N/A |
6/30/2017 | N/A | -4 | N/A | -2 | N/A |
3/31/2017 | N/A | -5 | N/A | -2 | N/A |
12/31/2016 | N/A | -4 | N/A | -1 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: GNPX is forecast to remain unprofitable over the next 3 years.
Winst versus markt: GNPX is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: GNPX is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: Insufficient data to determine if GNPX's revenue is forecast to grow faster than the US market.
Hoge groei-inkomsten: GNPX is forecast to have no revenue next year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if GNPX's Return on Equity is forecast to be high in 3 years time